相关实验视频

Updated: May 21, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

在癌症中准PD-1/PD-L1的多种类型抗体

Miaomiao Chen¹, Yuli Zhou², Kaicheng Bao¹

¹Department of Oncology, Shengjing Hospital of China Medical University, 36 Sanhao Road, Shenyang, 110004, China.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

|March 19, 2025

概括

针对编程细胞死亡蛋白1 (PD-1) /编程细胞死亡1联体1 (PD-L1) 的多种类型抗体提供了增强的癌症治疗疗效. 这些先进的疗法在克服耐药性和减少副作用方面表现有前途,与单药疗法相比.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
生物技术是生物技术.

背景情况:

免疫检查点抑制剂,特别是针对PD-1/PD-L1,已经改变了癌症治疗.
对单剂抗PD-1/PD-L1疗法的耐药性限制了临床有效性.
组合疗法可以提高反应率,但会增加不良事件.

研究的目的:

审查针对PD-1/PD-L1.1的多特异性抗体的结构,临床前基础和临床发展.
突出双特异性,三特异性和四特异性抗体在癌症治疗中的潜力.
讨论这些先进免疫疗法的挑战和未来方向.

主要方法:

对针对PD-1/PD-L1.1的多种特异抗体进行的临床前和临床研究的综合文献综述.
对抗体结构-功能关系和作用机制的分析.
对已批准和正在研究的多种特异抗体的临床试验数据的评估.

主要成果:

针对PD-1/PD-L1的几种双特异性抗体 (bsAbs) 已获得批准或正在临床试验中.
三特异性抗体 (TsAbs) 和四特异性抗体 (TetraMabs) 正成为新一代治疗方法.
多种类型的抗体显示出改善抗瘤活性和降低毒性的潜力.

结论:

多种类型的抗体代表了克服对PD-1/PD-L1阻塞的抗性的有希望的治疗策略.
这些药物提供了一种提高疗效的方法,同时可能减轻与组合疗法相关的副作用.
进一步的临床开发对于充分实现多种类型抗体在癌症治疗中的潜力至关重要.

更多相关视频

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cross-reactivity

Cross-reactivity

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...